NCT03208959View on ClinicalTrials.gov

A Trial of HTI-1090 in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 30, 2017

Primary Completion Date

November 1, 2018

Study Completion Date

January 23, 2019

Conditions
Advanced Solid Tumors
Interventions
DRUG

HTI-1090

IDO/TDO inhibitor

Trial Locations (1)

4101

Icon Cancer Care Centre, South Brisbane

All Listed Sponsors
lead

Atridia Pty Ltd.

INDUSTRY

NCT03208959 - A Trial of HTI-1090 in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter